Does enbrel work for psoriasis?

Does Enbrel work for psoriasis?

Enbrel (etanercept) is approved by the FDA to treat moderate to severe plaque psoriasis in adults and children 4 years and older. Clinical trials showed that 47% of patients reached PASI 75 after 12 weeks of twice-weekly 50 mg doses, compared to 4% of those receiving placebo.

What results do patients see in real life?

Long-term open-label extensions of the original trials tracked patients who stayed on continuous treatment. After 96 weeks, 57% of patients maintained PASI 75, and 30% reached PASI 90. Data from registries tracking everyday use show similar rates of skin clearance.

Does it help with psoriatic arthritis too?

Enbrel covers both skin and joints. Clinical data indicate 59% of patients with concurrent psoriatic arthritis achieved ACR20 after 24 weeks. Many patients who had failed other treatments reported less pain and less stiffness.

How does Enbrel compare with other biologics?

Enbrel has a longer history of use than newer TNF inhibitors and IL-17 or IL-23 blockers. Newer agents such as Cosentyx and Tremfya show higher skin-clearance rates in head-to-head trials, but Enbrel remains active against both skin and joint symptoms. Many patients who are sensitive to injection-site reactions or who are on older protocols still use Enbrel.

When does the Enbrel patent expire?

The main composition-of-matter patent expired in 2011. The last remaining biologic exclusivity ended in 2015. Since 2016, biosimilars have been available in the US under names like Eticovo and Erelzi. Biosimilars are priced 30-30% lower than the original brand.

Who makes Enbrel and how is it supplied?

Enbrel is produced by Amgen. It comes in pre-filled syringes, auto-injectors, and vial-and-sjector combinations. The 50 mg weekly or twice-weekly schedule is the most common protocol.

What side effects are patients asking about?

Patients most often ask about increased risk of serious infections, tuberculosis reactivation, and nerve demyelination. Registries show low rates of these events under proper screening.